A randomised, controlled, open-label, 48-week, study to asses differences in changes in plasma lipid profile between patients on saquinavir/ritonavir or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate and emtricitabine as a first-line regimen.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Atazanavir (Primary) ; Emtricitabine (Primary) ; Ritonavir (Primary) ; Saquinavir (Primary) ; Tenofovir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms BASIC
- 10 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Dec 2009 Results reported at 12th European AIDS Conference.
- 11 May 2007 New trial record.